When was BaseLaunch founded?

BaseLaunch was founded in 2017.

Where is BaseLaunch's headquarters located?

BaseLaunch's headquarters is located in Basel (Switzerland).

How big is BaseLaunch's investment team?

BaseLaunch has a team of 21, including 9 partners.

How many companies has BaseLaunch invested in?

BaseLaunch has invested in 25 companies, including TOLREMO therapeutics & Alentis Therapeutics.

Which companies has BaseLaunch invested in lately?

Engimmune Therapeutics & Alibion are the latest investments by BaseLaunch.

How many exits has BaseLaunch been involved in?

BaseLaunch's portfolio has seen 1 acquisition.

BaseLaunch - 2026 Investor Profile, Portfolio, Team & Investment Trends

BaseLaunch, an accelerator and incubator program founded in 2017, is based in Basel, Switzerland. With a presence in 4 countries, it has supported around 25 startups in sectors like Life Sciences, High Tech. As of Apr 2026, BaseLaunch has witnessed 1 portfolio exit. Most notable companies in its portfolio include TOLREMO therapeutics, Alentis Therapeutics and Synendos Therapeutics. The program is backed by a team of 21 people who primarily support Seed startups based in Switzerland. Its latest investment was a $15.9M Seed round in Engimmune Therapeutics on May 03, 2022, which also saw participation from Pureos Bioventures and Novo Holdings.

Key Metrics

Founded Year

2017

Location

Basel, Switzerland

Portfolio Companies

TOLREMO therapeutics, Alentis Therapeutics & 23 more

Sectors of Investment

Life Sciences, High Tech & 4 more

Stages of Investment

Seed & Grant (prize money)

Locations of Investment

Switzerland, Germany & 2 more

View BaseLaunch's full profile

BaseLaunch has a portfolio of 25 companies. Their most notable investments are in SiBreax and Alibion.Their portfolio spans across Switzerland, Germany, Greece and 1 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 3 other sectors, across stages such as Seed, Grant (prize money) stages. Here is the list of top investments by BaseLaunch:

1. TOLREMO therapeutics

TOLREMO therapeutics is a developer of small molecules that target novel drug resistance pathways involved in cancer. The company has developed a screening platform for developing novel anti-drug resistance cancer drugs, and is also exploring the possibility of combining existing drugs to prevent drug resistance in cancer.

Key facts about TOLREMO therapeutics

Founded Year: 2017
Location: Zurich (Switzerland)
Stage: Series A
Total Funding till date: $55.8M
Employee Count: 15 as on Oct 17, 2025
Investors: Zurcher Kantonalbank, Redalpine and 9 Others
Latest Funding Round: Series A, Sep 20, 2023, $*****
Highlight: Editors' Pick

2. Alentis Therapeutics

Developer of therapies for treating fibrosis, cirrhosis, and liver cancer. They have developed a gene expression platform. Their drug candidates (monoclonal antibodies) target a cell surface protein, which is being investigated for liver disease and cancer. The products include ALE-F02, CLDN1 for Liver Fibrosis (F3/F4) and kidney fibrosis, and ALE-C04, CLDN1 for Hepatocellular Carcinoma (HCC), and Cholangiocarcinoma.

Key facts about Alentis Therapeutics

Founded Year: 2019
Location: Basel (Switzerland)
Valuation: $*****
Stage: Series D
Total Funding till date: $366M
Employee Count: 67 as on Mar 31, 2026
Investors: RA Capital Management, Frazier Life Sciences and 14 Others
Latest Funding Round: Series D, Nov 12, 2024, $*****
Highlight: Editors' Pick

3. Synendos Therapeutics

Synendos Therapeutics is a developer of endocannabinoid modulators for the treatment of CNS disorders. It has developed pharmaceutical products to restore the natural function of the brain and treat neuropsychiatric disorders. The company is developing small molecules as selective endocannabinoid reuptake inhibitors that increase the levels of endogenous cannabinoids to treat CNS disorders caused by cannabinoid deficiency.

Key facts about Synendos Therapeutics

Founded Year: 2019
Location: Allschwil (Switzerland)
Stage: Series A
Total Funding till date: $26.2M
Employee Count: 7 as on Jul 01, 2024
Investors: Schroders Capital, Zurcher Kantonalbank and 11 Others
Latest Funding Round: Series A, Apr 20, 2021, $*****
Highlight: Editors' Pick

4. Isarna Therapeutics

Isarna Therapeutics develops TGF-B inhibitors that stimulate the human immune system to effectively treat ophthalmic, fibrotic diseases cancer. Its lead product ISTH0036 for ophthalmology is undergoing Phase 1 trials. Other candidates include ISTH1106 for fibrosis, ISTH0047, and ISTH1047 for oncology which are in pre-clinical stage. Its leading candidate ISTH0036 is a locked nucleic acid-modified antisense oligonucleotide selectively targeting the messenger ribonucleic acid (mRNA) of TGF-β2. The company received FDA orphan drug designation for ISTH0036, for the prevention of scarring post glaucoma filtration surgery.

Key facts about Isarna Therapeutics

Founded Year: 1998
Location: Munich (Germany)
Stage: Series F
Total Funding till date: $158M
Employee Count: 7 as on Feb 28, 2026
Investors: Bayern Kapital, MIG Fonds and 9 Others
Latest Funding Round: Series F, Apr 24, 2014, $*****
Highlight: Editors' Pick

5. Anaveon

Developer of immunotherapies for treating cancers. The company is developing IL-2 complexes which selectively enhance effector T cell functions and act as an immune adjuvant. It is given as monotherapy or in combination with other therapies. Also, it has a pipeline that includes additional programs that leverage targeted cytokines for a range of immune-mediated diseases.

Key facts about Anaveon

Founded Year: 2017
Location: Zurich (Switzerland)
Stage: Series B
Total Funding till date: $157M
Employee Count: 25 as on Mar 31, 2026
Investors: Pontifax, Cowen and 5 Others
Latest Funding Round: Series B, Dec 16, 2021, $*****

View the full list of portfolio companies

BaseLaunch has invested in 25 companies over the last 9 years, with an average of 0 new investment annually in the last 5 years. Its most recent first time investment was in Engimmune Therapeutics.

Here are BaseLaunch's Year-on-Year Investment Trends:

Year	No. of Investments
Year	1^st Round	Follow-on	Total
2026 (YTD)	0	0	0
2025	0	0	0
2024	0	0	0
2023	0	0	0
2022	1	0	1
2021	0	0	0
2020	0	0	0
2019	4	0	4
2018	1	0	1
2017	1	0	1

View all investments by BaseLaunch

BaseLaunch has made 5 investments in Seed stage with an average round size of $3.98M and 2 investments in Grant (prize money) stage.

Here are BaseLaunch's investments by stage:

Stage of entry	No. of Investments
Seed	5
Grant (prize money)	2

Note: We have considered here, only first round of investments

View all investments by BaseLaunch

BaseLaunch has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Consumer and HealthTech. Notably, it has invested in 24 Tech companies, 22 Enterprise (B2B) companies, 2 Software companies and 1 company focusing on Tech hardware.

Here are BaseLaunch's investments by sector:

Sector	No. of Investments
Life Sciences	7
High Tech	2
Consumer	1
HealthTech	1

Note: We have considered here, only first round of investments

View all investments by BaseLaunch

BaseLaunch has made most investments in Switzerland (7).

View all investments by BaseLaunch

BaseLaunch has not made any investment in 2026 so far.

Here are the most recent investments by BaseLaunch:

Filter this list

Date	Company	Location	Round Details	Round Amount	Co-Investors
May 03, 2022	Engimmune Therapeutics	Switzerland	Seed	2898	Pureos Bioventures [+2]
Oct 04, 2019	Alibion	Switzerland	Seed	8774	-
Oct 04, 2019	SunRegen Healthcare	Switzerland	Seed	6111	-
Jan 22, 2019	Synendos Therapeutics	Switzerland	Grant (prize money)	2739	-
Jan 22, 2019	Pattern Biosciences	Switzerland	Grant (prize money)	2525	-

See more recent investments made by BaseLaunch

1 company from BaseLaunch's portfolio has been acquired. The most recent acquisition was T3 Pharma in Nov 2023 by Boehringer Ingelheim for $*****.

Here are BaseLaunch's portfolio companies that got acquired most recently:

Filter this list

Company	Acquisition Date	First Invested on	First Round of Investment	Round Size
T3 Pharma	Nov 22, 2023	-	-	6789

View all acquired companies in BaseLaunch's portfolio

BaseLaunch has a team of 21 members including 9 Partners and 5 Principals located in Switzerland, Denmark and 3 more locations. BaseLaunch's team does not sit on the board of any company as of now.

Here is a list of top team members in BaseLaunch:

Name	Designation	Location	Board Memberships	Contact Details
Ximing Ding	Partner	Zurich	-	1 Email
Daniel Timmermann	Partner	Copenhagen	-	-
Joachim Vogt	Partner	Ludwigshafen Am Rhein	-	-
Neil Anderson	Partner	Copenhagen	-	-
Valerie Hepp	Partner	Zurich	-	-
Carsten Kroll	Partner	Basel	-	-
Christopher Kim	Partner	United States	-	-
Huaizheng Peng	Partner	London	-	-
James Stearns	Partner	United Kingdom	-	-
Virginia Ballotta	Principal	Basel	-	1 Email
Neil Goldsmith	Principal	Copenhagen	-	1 Email

View team details of BaseLaunch

Over the past 9 years, 16 investors have co-invested in BaseLaunch's portfolio companies. This includes funds and angels.

Invested before BaseLaunch: Europa and EIC Fund have invested in rounds before BaseLaunch. There are 2 companies where Europa has invested before BaseLaunch and 1 company where EIC Fund has invested before BaseLaunch.
Top Co-investors of BaseLaunch: 3 investors entered a company along with BaseLaunch. These include investors like Pureos Bioventures (1 company).
Invested after BaseLaunch: A total of 11 investors have invested in BaseLaunch's portfolio after their investments. Top Investors include EIC Fund (2 companies) and Ysios Capital (1 company).